AAAAAA

   
Results: 1-14 |
Results: 14
The role of phagocytes in HIV-related oxidative stress
Authors: Elbim, C Pillet, S Prevost, MH Preira, A Girard, PM Rogine, N Hakim, J Israel, N Gougerot-Pocidalo, MA
Citation: C. Elbim et al., The role of phagocytes in HIV-related oxidative stress, J CLIN VIRO, 20(3), 2001, pp. 99-109
Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection
Authors: Girard, PM Schneider, V Dehee, A Mariot, P Jacomet, C Delphin, N Damond, F Carcelain, G Autran, B Saimot, AG Nicolas, JC Rozenbaum, W
Citation: Pm. Girard et al., Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection, AIDS, 15(2), 2001, pp. 275-277
Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study
Authors: Serfaty, L Costagliola, D Wendum, D Picard, O Meyohas, MC Girard, PM Lebas, J Delamare, C Poupon, R Housset, C
Citation: L. Serfaty et al., Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study, AIDS, 15(15), 2001, pp. 2011-2016
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay
Authors: Desire, N Dehee, A Schneider, V Jacomet, C Goujon, C Girard, PM Rozenbaum, W Nicolas, JC
Citation: N. Desire et al., Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay, J CLIN MICR, 39(4), 2001, pp. 1303-1310
Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection:Pharmacokinetics, tolerability, and efficacy
Authors: Girard, PM Pegram, PS Diquet, B Anderson, R Raffi, F Tubiana, R Sereni, D Boerner, D
Citation: Pm. Girard et al., Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection:Pharmacokinetics, tolerability, and efficacy, J ACQ IMM D, 23(3), 2000, pp. 227-235
Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens
Authors: Girard, PM Guiguet, M Bollens, D Goderel, I Meyohas, MC Lecomte, I Raguin, G Frottier, J Rozenbaum, W Jaillon, P
Citation: Pm. Girard et al., Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens, CLIN INF D, 31(4), 2000, pp. 987-994
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening
Authors: Gozalbes, R Brun-Pascaud, M Garcia-Domenech, R Galvez, J Girard, PM Doucet, JP Derouin, F
Citation: R. Gozalbes et al., Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening, ANTIM AG CH, 44(10), 2000, pp. 2764-2770
Anti-Toxoplasma activities of 24 quinolones and fluoroquinolones in vitro:Prediction of activity by molecular topology and virtual computational techniques
Authors: Gozalbes, R Brun-Pascaud, M Garcia-Domenech, R Galvez, J Girard, PM Doucet, JP Derouin, F
Citation: R. Gozalbes et al., Anti-Toxoplasma activities of 24 quinolones and fluoroquinolones in vitro:Prediction of activity by molecular topology and virtual computational techniques, ANTIM AG CH, 44(10), 2000, pp. 2771-2776
Radiosensitivity in Nijmegen Breakage syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects
Authors: Girard, PM Foray, N Stumm, M Waugh, A Riballo, E Maser, RS Phillips, WP Petrini, J Arlett, CF Jeggo, PA
Citation: Pm. Girard et al., Radiosensitivity in Nijmegen Breakage syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects, CANCER RES, 60(17), 2000, pp. 4881-4888
Prospective study of CD8(+) lymphocyte activation in relation to viral load in HIV-infected patients with >= 400 CD4(+) lymphocytes per microliter
Authors: Bouscarat, F Levacher, M Dazza, MC Chau, F Desforges, B Muffat-Joly, M Matheron, S Girard, PM Sinet, M
Citation: F. Bouscarat et al., Prospective study of CD8(+) lymphocyte activation in relation to viral load in HIV-infected patients with >= 400 CD4(+) lymphocytes per microliter, AIDS RES H, 15(16), 1999, pp. 1419-1425
T cell changes after combined nucleoside analogue therapy in HIV primary infection
Authors: Carcelain, G Blanc, C Leibowitch, J Mariot, P Mathez, D Schneider, V Saimot, AG Damond, F Simon, F Debre, P Autran, B Girard, PM
Citation: G. Carcelain et al., T cell changes after combined nucleoside analogue therapy in HIV primary infection, AIDS, 13(9), 1999, pp. 1077-1081
Monocyte expression of adhesion molecules in HIV-infected patients: Variations according to disease stage and possible pathogenic role
Authors: Pillet, S Prevost, MH Preira, A Girard, PM Rogine, N Hakim, J Gougerot-Pocidalo, MA Elbim, C
Citation: S. Pillet et al., Monocyte expression of adhesion molecules in HIV-infected patients: Variations according to disease stage and possible pathogenic role, LAB INV, 79(7), 1999, pp. 815-822
Redox and activation status of monocytes from human immunodeficiency virus-infected patients: Relationship with viral load
Authors: Elbim, C Pillet, S Prevost, MH Preira, A Girard, PM Rogine, N Matusani, H Hakim, J Israel, N Gougerot-Pocidalo, MA
Citation: C. Elbim et al., Redox and activation status of monocytes from human immunodeficiency virus-infected patients: Relationship with viral load, J VIROLOGY, 73(6), 1999, pp. 4561-4566
Restoration of normal interleukin-2 production by CD4(+) T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy
Authors: Weiss, L Ancuta, P Girard, PM Bouhlal, H Roux, A Cavaillon, NH Kazatchkine, MD
Citation: L. Weiss et al., Restoration of normal interleukin-2 production by CD4(+) T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy, J INFEC DIS, 180(4), 1999, pp. 1057-1063
Risultati: 1-14 |